NASDAQ · NPCE
Healthcare · Medical - Devices
$12.30
Up+$0.19 (+1.54%)
Updated Nov 2, 2026, 5:31 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NPCE
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
NPCE closed at $12.30 after 20 trading sessions, down 6.96% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $13.01 | $13.10 | $12.25 | $12.30 | 80.9K |
| Oct 29, 2026 | $13.12 | $13.45 | $12.94 | $13.01 | 104.56K |
| Oct 28, 2026 | $12.83 | $13.33 | $12.74 | $12.93 | 189.53K |
| Oct 27, 2026 | $13.03 | $13.16 | $12.91 | $13.02 | 67.24K |
| Oct 26, 2026 | $12.90 | $13.215 | $12.64 | $12.99 | 67.34K |
| Oct 23, 2026 | $12.76 | $13.07 | $12.76 | $12.91 | 69.07K |
| Oct 22, 2026 | $13.05 | $13.43 | $12.92 | $13.14 | 97.95K |
| Oct 21, 2026 | $13.51 | $13.69 | $13.03 | $13.05 | 64.25K |
| Oct 20, 2026 | $12.84 | $13.53 | $12.81 | $13.51 | 116.88K |
| Oct 19, 2026 | $12.28 | $12.80 | $12.16 | $12.77 | 117.45K |
| Oct 16, 2026 | $12.85 | $12.85 | $12.13 | $12.24 | 156.25K |
| Oct 15, 2026 | $12.51 | $13.00 | $12.51 | $12.78 | 86.62K |
| Oct 14, 2026 | $12.58 | $13.04 | $12.475 | $12.56 | 90.02K |
| Oct 13, 2026 | $13.06 | $13.265 | $12.68 | $12.68 | 66.78K |
| Oct 12, 2026 | $12.52 | $13.02 | $12.48 | $13.00 | 63.3K |
| Oct 9, 2026 | $12.39 | $12.70 | $12.38 | $12.67 | 72.64K |
| Oct 8, 2026 | $12.66 | $12.66 | $12.28 | $12.39 | 142.58K |
| Oct 7, 2026 | $12.58 | $13.06 | $12.51 | $12.76 | 127.18K |
| Oct 6, 2026 | $13.38 | $13.38 | $12.66 | $12.67 | 83.59K |
| Oct 5, 2026 | $12.64 | $13.26 | $12.50 | $13.22 | 149.43K |
The latest Smart Investors Daily articles mentioning NPCE.
Company
Market Activity
Research & News
NPCE research
Company profile and research snapshot.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | Keybanc | Overweight | — |
| Jul 29, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 23, 2026 | Mizuho | Outperform | — |
| May 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 27, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 18, 2026
Keybanc analyst Brett Fishbin initiates coverage on NeuroPace (NASDAQ:NPCE) with a Overweight rating and announces Price Target of $18.
Yahoo · Sep 10, 2026
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Sep 4, 2026
NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
Yahoo · Sep 1, 2026
MOUNTAIN VIEW, Calif., September 01, 2026--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NPCE.
